[{"id":"9f0a2252-2d03-40ea-9677-2060190e337e","acronym":"ARROS-1","url":"https://clinicaltrials.gov/study/NCT05118789","created_at":"2021-11-12T13:53:34.949Z","updated_at":"2024-07-02T16:35:15.663Z","phase":"Phase 1/2","brief_title":"A Study of NVL-520 in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1)","source_id_and_acronym":"NCT05118789 - ARROS-1","lead_sponsor":"Nuvalent Inc.","biomarkers":" ROS1","pipe":" | ","alterations":" ROS1 rearrangement","tags":["ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ROS1 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e zidesamtinib (NVL-520)"],"overall_status":"Recruiting","enrollment":" Enrollment 359","initiation":"Initiation: 01/04/2022","start_date":" 01/04/2022","primary_txt":" Primary completion: 10/31/2025","primary_completion_date":" 10/31/2025","study_txt":" Completion: 10/31/2026","study_completion_date":" 10/31/2026","last_update_posted":"2024-03-08"}]